Coherus Biosciences presents final Phase 2 clinical casdozokitug data

Coherus BioSciences (CHRS) announced final data from its Phase 2 open label clinical trial evaluating casdozokitug, a selective and potent Interleukin (IL)-27-targeting antibody, in combination with atezolizumab and bevacizumab in treatment naive patients with unresectable locally advanced or metastatic hepatocellular carcinoma. These data are being presented at the 2025 ASCO Gastrointestinal Cancers Symposium taking place January 23-25, 2025, in San Francisco, California. These data showed an overall response rate of 38% compared to initially announced 27%, and complete responses per RECIST v1.1 increased to 17.2% compared to previously announced 10.3% and initial assessment of 0%, demonstrating both an increase in ORR and a deepening of responses compared to previous datasets. Importantly, responses were seen in viral and nonviral disease, and toxicity was consistent with the known safety profiles of atezolizumab and bevacizumab, with no new safety signals identified.